Deals

Drug Veterans Court French Upstart With Plaque Attack Remedy

Lock
This article is for subscribers only.

Drugmakers desperate for innovative medicines are courting a tiny French company whose lab holds a product that may transform the treatment of heart attacks.

Cerenis Therapeutics SA, a closely held company, is testing a compound in a new class of drugs that mimic high-density lipoprotein, also known as good cholesterol, to purge arteries clogged by plaque.